A Leader in Medication

Management and

Patient Safety

October 6th, 2014

Exhibit 99.2

2

IMPORTANT INFORMATION FOR INVESTORS

In connection with the proposed transaction, BD will file with the SEC a registration statement on Form S–4 that will

constitute a prospectus of BD and include a proxy statement of CareFusion. BD and CareFusion also plan to file other

relevant documents with the SEC regarding the proposed transaction. INVESTORS ARE URGED TO READ THE

PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IF AND WHEN

THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free

copy of the proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by BD and

CareFusion

with

the

SEC

at

the

SEC’s

website

at

www.sec.gov.

In

addition,

you

will

be

able

to

obtain

free

copies

of

these

documents by phone, email or written request by contacting the investor relations department of BD or CareFusion at the

following: Monique Dolecki, BD Investor Relations 201-847-5378 or Jim Mazzola, CareFusion Investor Relations  858-

617-1203.

PARTICIPANTS IN THE SOLICITATION

BD and CareFusion and their respective directors and executive officers and other members of management and

employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.

Information about BD's directors and executive officers is available in BD's proxy statement dated December 19, 2013, for

its

2014

Annual

Meeting

of

Shareholders

and

in

its

subsequent

filings

with

the

SEC.

Information

about

CareFusion’s

directors and executive officers is available in CareFusion's proxy statement dated September 25, 2014, for its 2014

Annual Meeting of Stockholders.

Other information regarding the participants in the proxy solicitation and a description of

their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus

and

other

relevant

materials

to

be

filed

with

the

SEC

regarding

the

merger

when

they

become

available.

Investors

should

read the proxy statement/prospectus carefully when it becomes available before making any voting or investment

decisions.

You may obtain free copies of these documents from BD or CareFusion as indicated above. This slide

presentation

shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any

sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or

qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of

a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

3

This slide presentation contains certain estimates and other forward-looking statements (as defined under Federal securities laws). 

Forward looking statements generally are accompanied by words such as “will”, "expect", "outlook" or other similar words, phrases or

expressions.  These forward-looking statements include statements regarding the estimated or anticipated future results of BD, and

of the combined company following BD’s proposed acquisition of CareFusion, the anticipated benefits of the proposed combination,

including estimated synergies, the expected timing of completion of the transaction and other statements that are not historical facts.

These statements are based on the current expectations of BD and CareFusion management and are not predictions of actual

performance.  These statements are subject to a number of risks and uncertainties regarding BD and CareFusion’s respective

businesses and the proposed acquisition, and actual results may differ materially.  These risks and uncertainties include, but are not

limited to, the ability of the parties to successfully close the proposed acquisition, including the risk that the required regulatory

approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company

or the expected benefits of the transaction; risks relating to the integration of CareFusion’s operations, products and employees into

BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be

realized within the expected timeframe; the outcome of any legal proceedings related to the proposed merger; access to available

financing for the refinancing of BD’s or CareFusion’s debt on a timely basis and reasonable terms; the ability to market and sell

CareFusion’s products in new markets, including the ability to obtain necessary regulatory product registrations and clearances; the

loss of key senior management or other associates; the anticipated demand for BD’s and CareFusion’s products, including the risk of

future reductions in government healthcare funding, changes in reimbursement rates or changes in healthcare practices that could

result in lower utilization rates or pricing pressures; the impact of competition in the medical device industry; the risks of fluctuations

in interest or foreign currency exchange rates; product liability claims; difficulties inherent in product development, including the

timing or outcome of product development efforts, the ability to obtain regulatory approvals and clearances and the timing and market

success of product launches; risks relating to fluctuations in the cost and availability of raw materials and other sourced products and

the ability to maintain favorable supplier arrangements and relationships; successful compliance with governmental regulations

applicable to BD, CareFusion and the combined company; changes in regional, national or foreign economic conditions;

uncertainties of litigation, as well as other factors discussed in BD’s and CareFusion’s respective filings with the Securities Exchange

Commission.  BD and CareFusion do not intend to update any forward-looking statements to reflect events or circumstances after

the date hereof, except as required by applicable laws or regulations.

4

Speakers on Today’s Call

1

Christopher Reidy

CFO and EVP,

Administration

Becton, Dickinson & Co.

Kieran Gallahue

Chairman & CEO

CareFusion Corp.

Vince Forlenza

Chairman, CEO &

President

Becton, Dickinson & Co.

5

Accelerates

BD’s

strategy

to

deliver complete solutions that

meet evolving industry needs

Builds

scale

and

depth

to

create unique growth

opportunities, leveraging

BD’s international footprint

Creates

meaningful

value

for

shareholders, customers and

employees around the world

Compelling Strategic Transaction

Compelling Strategic Transaction

$12 billion in combined

annualized revenues

46,000 employees

worldwide

Presence in almost every

country in the world

Significantly increases BD’s

addressable opportunity

A Leader in Medication

Management and

Patient Safety

6

Key Highlights

BD is a company with strong values and a track record of success

Announcement accelerates CareFusion’s plans to build greater scale

New growth opportunities for products in emerging markets and

expands global reach by leveraging BD’s international infrastructure

Offers a complete suite of medication management and patient safety

solutions

The hard work of CareFusion’s 17,000 employees got us here today

7

Accelerates BD’s Strategy

Built targeted M&A capabilities

Emerging market investments

Enhanced operational efficiencies

R&D spending reallocation 

2010 to 2012

2013 to 2014

Today

Becoming a provider of complete

healthcare solutions

Moved into near adjacencies

Accelerated revenue growth

Delivered higher quality of earnings

New products as a percentage of sales increased from 8% to 15%

Improving outcomes and quality of care

Lowering cost of healthcare delivery

Increasing access to healthcare

Optimizing patient and healthcare worker safety

Addressing

Unmet Needs:

8

Builds Scale and Depth in

Medication Management 

BD

Prepare

Dispense

Administer

Monitor

CareFusion

BD+CareFusion

More than doubles BD Medical’s

addressable opportunity from

about $8B to $16B

Becomes a global leader in medication

management, with a leading informatics

platform across value chain

Leading Position

New/Small Position

Smart Solution

9

Leveraging BD’s

International Footprint

Leverage BD’s investments in Asia

Pacific, Latin America, EMEA

Accelerate uptake of CareFusion

products and solutions tailored

to these markets

75%

Developed

Emerging

U.S.

20%

5%

42%

Developed

Emerging

U.S.

33%

25%

Emerging

Optimize end-to-end medication

management process from drug

preparation to dispensing and

administration

Accelerate core and new product

uptake via strengthening call points

Developed

Opportunity for Growth

10

Transaction

Terms

Represents per share consideration for CareFusion shareholders of:

Financing and

Balance Sheet

Impact

Permanent financing expected to be in the form of available cash

and unsecured notes

BD currently has $9 billion of fully committed bridge financing

in place

Timing

Transaction expected to close in first half of calendar year 2015,

subject to regulatory and CareFusion shareholder approvals

Transaction Overview

BD to assume ~$2.0 billion of CareFusion debt and $1.8 billion of cash

$49.00 in cash

0.0777 shares of new BD shares

CareFusion shareholders to own approximately 8% of the combined

company

Total consideration of $12.2 billion in cash and BD stock

11

Creates Meaningful Value for

Shareholders

Growth

Synergies

Earnings

Impact and

Returns

Balance Sheet

Implications

Capital Allocation

Policy

Stronger platform for diversified growth

Leverage BD’s strong international presence to accelerate growth of

CareFusion products

Consistent with BD’s long term revenue growth aspirations

Approximately $250 million of cost synergies

Fully realized in FY 2018

Reduced overhead expenses and efficiencies resulting from the

combined operational and manufacturing footprint

Attractive return profile and strong cash flow

Double-digit accretive to cash EPS in the first full year, accretive to

GAAP EPS by FY 2018

Deliver strong ROIC

Expand EBITDA margins

Commitment to investment grade rating

Pro forma leverage ratio of ~4.3x LTM Adjusted EBITDA

Net leverage ratio of ~3.2x

Committed to maintaining solid investment grade rating

Commitment to grow the current dividend per share in line with our

expectations for long term earnings growth

Expect to suspend share buyback program in the near-term to focus

on deleveraging and the dividend

12

Detailed Execution Plan for a

Detailed Execution Plan for a

Seamless Integration

Seamless Integration

Designated integration planning team led by BD Chief Operating

Officer Bill Kozy

Team includes senior members of both organizations by geography,

function and business unit

Confident in ability to achieve identified cost synergies

CareFusion businesses will be reported within BD Medical segment

Building dynamic organization that brings together two world class

companies

13

Compelling Strategic Transaction

Compelling Strategic Transaction

A Leader in Medication

Management and

Patient Safety

$12 billion in combined

annualized revenues

46,000 employees

worldwide

Presence in almost every

country around the world

Significantly

increases

BD’s

addressable opportunity

14

BD,

BD

Logo

and

all

other

trademarks

are

the

property

of

Becton,

Dickinson

and

Company.